Health Economics›Classical Hodgkin lymphoma›Untreated

Untreated

Classical Hodgkin lymphoma · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ChlVPP/PABIOE Variant #01 Partial	—	R 8 351	28d	—	—	~4	~R 33 403 indirect	—
LOPP/EVAP Variant #01 Partial	—	R 7 178	28d	—	—	~8	~R 28 809 indirect	—
COPP/ABVD Variant #01 Partial	—	R 6 789	28d	—	—	~2	~R 13 578 indirect	—
MOPP/ABVD Variant #01 Partial	—	R 6 463	28d	—	—	~6	~R 38 621 indirect	—
ABVDm Variant #01 Partial	—	R 6 088	28d	—	—	~3	~R 18 263 indirect	—
Doxorubicin and Vinblastine Variant #01	—	R 3 452	28d	—	—	~3	~R 10 356 indirect	—
CVPP (Cyclophosphamide) Variant #01 Partial	—	R 3 229	30d	—	—	~6	~R 19 372 indirect	—
CVPP Variant #01 Partial	—	R 2 928	28d	—	—	~12	~R 34 819 indirect	—
MVPP Variant #01 Partial	—	R 2 928	28d	—	—	~6	~R 17 449 indirect	—
COMP Variant #01 Partial	—	R 2 132	37d	—	—	~1	~R 2 132 indirect	—
LOPP Variant #01 Partial	—	R 1 879	28d	—	—	~8	~R 15 034 indirect	—
BCVPP Variant #01 Partial	—	R 1 637	28d	—	—	~6	~R 9 822 indirect	—
Vinblastine monotherapy Variant #01	—	R 1 444	14d	—	—	~2	~R 2 888 indirect	—
COPP (CCNU) Variant #01 Partial	—	R 693	28d	—	—	~6	~R 4 038 indirect	—
SCAB Variant #01 Partial	—	R 507	30d	—	—	~2	~R 1 014 indirect	—
NOVP Partial	—	—	—	—	—	—	—	—
Mechlorethamine monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

17 of 17 regimens shown